References
- Gupta N, Noy A. Fourth complete remission (CR) with irinotecan after both auto and allogeneic transplant for diffuse large b cell lymphoma (DLBCL). Leuk Lymphoma, in press.
- Wall ME, Wani MC, Cook CE, et al Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J Am Chem Soc 1996;88:3888.
- Drewinko B, Freireich EJ, Gottlieb JA. Lethal activity of camptothecin sodium on human lymphoma cells. Cancer Res 1974;34:747–750.
- Kraut EH, Balcerzak SP, Young D, et al A phase II study of topotecan in non-Hodgkin's lymphoma: an Ohio State University phase II research consortium study. Cancer Invest 2002;20:174–179.
- Crump M, Couban S, Meyer R, et al Phase II study of sequential topotecan and etoposide in patients with intermediate grade non-Hodgkin's lymphoma: a National Cancer Institute of Canada Clinical Trials Group study. Leuk Lymphoma 2002;43:1581–1587.
- Younes A, Preti HA, Hagemeister FB, et al Paclitaxel plus topotecan treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma. Ann Oncol 2001;12: 923–927.
- Smith SM, Johnson JL, Niedzwiecki D, et al Sequential doxorubicin and topotecan in relapsed/refractory aggressive non-Hodgkin's lymphoma: results of CALGB 59906. Leuk Lymphoma 2006;47:1511–1517.
- Ohno R, Okada K, Masaoka T, et al An early phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma. J Clin Oncol 1990;8: 1907–1912.
- Tsuda H, Takatsuki K, Ohno R, et al Treatment of adult T-cell leukaemia-lymphoma with irinotecan hydrochloride (CPT-11). CPT-11 Study Group on hematological malignancy. Br J Cancer 1994;70:771–774.
- Ribrag V, Koscielny S, Vantelon JM, et al Phase II trial of irinotecan (CPT-11) in relapsed or refractory non-Hodgkin's lymphomas. Leuk Lymphoma 2003;44:1529–1533.
- Sarris AH, Phan A, Goy A, et al Irinotecan in relapsed or refractory non-Hodgkin's lymphomas. Indications of activity in a phase II trial. Oncology (Williston Park) 2002;16(8 Suppl 7):27–31.
- Saotome T, Takagi T, Sakai C, et al Combination chemotherapy with irinotecan and adriamycin for refractory and relapsed non-Hodgkin's lymphoma. Ann Oncol 2000;11:115–116.
- Niitsu N, Kohuri M, Higashihara M, et al Phase II study of the CPT-11, mitoxantrone and dexamethasone regimen in combination with rituximab in elderly patients with relapsed diffuse large B-cell lymphoma. Cancer Sci 2006;97: 933–937.
- Niitsu N, Kohori M, Higashihara M, et al Phase II study of the irinotecan (CPT-11), mitoxantrone and dexamethasone regimen in elderly patients with relapsed or refractory peripheral T-cell lymphoma. Cancer Sci 2007; 98:109–112.
- Sapra P, Mehlig M, Malaby J, et al EZN-2208, a novel polyethyleneglycol-SN38 conjugate, therapy results in cures of animals bearing aggressive non-Hodgkin's lymphoma models. Haematologica 2008:93(Suppl 1):114 (Abstract 0281).
- Numbenjapon T, Wang J, Colcher D, et al Preclinical results of camptothecin-polymer conjugate (IT-101) in multiple human lymphoma xenograft models. Clin Cancer Res 2009; 15:4365–4373.
- Oliver JC, Yen Y, Synold TW, et al A dose-finding pharmacokinetic study of IT-101, the first de novo designed nanoparticle therapeutic, in refractory solid tumors. J Clin Oncol 2008;26 (Suppl): abstr 14538.